Abstract
Epilepsy is a complex neurological disorder which has plagued the human population through the ages and continues to affect about 50 million people worldwide. A better understanding of the pathogenesis of epilepsy unmasks various molecular targets for the treatment of epilepsy. The currently used antiepileptic drugs (AEDs) predominately target voltage-gated ion channels (Na+, Ca2+ and K+), GABAA receptor, glutamate receptor, synaptic vesicle 2A (SV2A) protein and carbonic anhydrase (CA). One group of AEDs acts on a single target while another group acts via multiple targets to control seizure episodes. AEDs which act via multiple mechanisms or polypharmacological mechanisms of action have appeared as broad spectrum anticonvulsant agent and therefore, they provide a better choice to clinicians to manage drug-resistant epilepsies and various other epileptic syndromes. For example, polypharmacological AEDs such as PB, VPA, OXC, FBM etc. are vital for managing epilepsy successfully, since decades. In literature there is no review available which exclusively highlights the polypharmacological mechanisms of action of existing AEDs as well as new emerging molecules. This review covers running marketed AEDs, clinical trial drugs as well as potent preclinical molecules which displayed anti-epileptic activity via multiple mechanisms of action and this appraisal will surely provide a base for discovering potent multi-targeted AEDs.
Keywords: Polypharmacology, epilepsy, antiepileptic drugs, mechanism of action.
Current Pharmaceutical Design
Title:Polypharmacological Drugs in the Treatment of Epilepsy: The Comprehensive Review of Marketed and New Emerging Molecules
Volume: 22 Issue: 21
Author(s): Shikha Kumari, Chandra Bhushan Mishra and Manisha Tiwari
Affiliation:
Keywords: Polypharmacology, epilepsy, antiepileptic drugs, mechanism of action.
Abstract: Epilepsy is a complex neurological disorder which has plagued the human population through the ages and continues to affect about 50 million people worldwide. A better understanding of the pathogenesis of epilepsy unmasks various molecular targets for the treatment of epilepsy. The currently used antiepileptic drugs (AEDs) predominately target voltage-gated ion channels (Na+, Ca2+ and K+), GABAA receptor, glutamate receptor, synaptic vesicle 2A (SV2A) protein and carbonic anhydrase (CA). One group of AEDs acts on a single target while another group acts via multiple targets to control seizure episodes. AEDs which act via multiple mechanisms or polypharmacological mechanisms of action have appeared as broad spectrum anticonvulsant agent and therefore, they provide a better choice to clinicians to manage drug-resistant epilepsies and various other epileptic syndromes. For example, polypharmacological AEDs such as PB, VPA, OXC, FBM etc. are vital for managing epilepsy successfully, since decades. In literature there is no review available which exclusively highlights the polypharmacological mechanisms of action of existing AEDs as well as new emerging molecules. This review covers running marketed AEDs, clinical trial drugs as well as potent preclinical molecules which displayed anti-epileptic activity via multiple mechanisms of action and this appraisal will surely provide a base for discovering potent multi-targeted AEDs.
Export Options
About this article
Cite this article as:
Kumari Shikha, Bhushan Mishra Chandra and Tiwari Manisha, Polypharmacological Drugs in the Treatment of Epilepsy: The Comprehensive Review of Marketed and New Emerging Molecules, Current Pharmaceutical Design 2016; 22 (21) . https://dx.doi.org/10.2174/1381612822666160226144200
DOI https://dx.doi.org/10.2174/1381612822666160226144200 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets How Accurate is Subjective Reporting of Childhood Sleep Patterns? A Review of the Literature and Implications for Practice
Current Pediatric Reviews The Role of Newer Antiglutamatergic Agents as Mood-Stabilizers in Bipolar Disorder
Current Drug Targets Review of Somnambulism in Children
Current Pediatric Reviews High-Frequency Oscillations and Epileptogenic Network
Current Neuropharmacology Comparison of Status Epilepticus Models Induced by Pilocarpine and Nerve Agents - A Systematic Review of the Underlying Aetiology and Adopted Therapeutic Approaches
Current Medicinal Chemistry UCLA’s Molecular Screening Shared Resource: Enhancing Small Molecule Discovery with Functional Genomics and New Technology
Combinatorial Chemistry & High Throughput Screening Managing Expectations in the Transition to Proof of Concept Studies
Reviews on Recent Clinical Trials The Vitamin D Neuroendocrine System as a Target for Novel Neurotropic Drugs
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Selection: Special Issue on Metabotropic Glutamate Receptors)
Current Neuropharmacology Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience Synthesis and Screening of Substituted Thiosemicarbazone Derivatives: An Approach towards Novel Anticonvulsant Search
Central Nervous System Agents in Medicinal Chemistry Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases
Current Clinical Pharmacology Clinical Neurophysiology of Brain Plasticity in Aging Brain
Current Pharmaceutical Design Ion Channels as Important Targets for Antiepileptic Drug Design
Current Drug Targets Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology In-vitro Functionality of Clozapine Biphasic Release Minitablet Using Advanced Statistical Tools
Drug Delivery Letters Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design